Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia

Jose Cadena; George R. Thompson; Tony T. Ho; Edward Medina; Darrel W. Hughes; Thomas F. Patterson

doi:10.1016/j.diagmicrobio.2009.03.019

Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia

Jose Cadena, George R. Thompson, Tony T. Ho, Edward Medina, Darrel W. Hughes, Thomas F. Patterson

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Tumor necrosis factor α antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.

Original language	English (US)
Pages (from-to)	327-330
Number of pages	4
Journal	Diagnostic Microbiology and Infectious Disease
Volume	64
Issue number	3
DOIs	https://doi.org/10.1016/j.diagmicrobio.2009.03.019
State	Published - Jul 2009

Keywords

Adalimumab
Cryptococcus
Immune reconstitution
TNF-α inhibitors

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.diagmicrobio.2009.03.019

Cite this

Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia. / Cadena, Jose ; Thompson, George R.; Ho, Tony T.; Medina, Edward; Hughes, Darrel W.; Patterson, Thomas F.

In: Diagnostic Microbiology and Infectious Disease, Vol. 64, No. 3, 07.2009, p. 327-330.

Research output: Contribution to journal › Article › peer-review

@article{8f59827095f443bbbdd9a14e0dc0889e,

title = "Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia",

abstract = "Tumor necrosis factor α antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.",

keywords = "Adalimumab, Cryptococcus, Immune reconstitution, TNF-α inhibitors",

author = "Jose Cadena and Thompson, {George R.} and Ho, {Tony T.} and Edward Medina and Hughes, {Darrel W.} and Patterson, {Thomas F.}",

year = "2009",

month = jul,

doi = "10.1016/j.diagmicrobio.2009.03.019",

language = "English (US)",

volume = "64",

pages = "327--330",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia

AU - Cadena, Jose

AU - Thompson, George R.

AU - Ho, Tony T.

AU - Medina, Edward

AU - Hughes, Darrel W.

AU - Patterson, Thomas F.

PY - 2009/7

Y1 - 2009/7

N2 - Tumor necrosis factor α antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.

AB - Tumor necrosis factor α antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.

KW - Adalimumab

KW - Cryptococcus

KW - Immune reconstitution

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=66149174923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149174923&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2009.03.019

DO - 10.1016/j.diagmicrobio.2009.03.019

M3 - Article

C2 - 19501793

AN - SCOPUS:66149174923

VL - 64

SP - 327

EP - 330

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 3

ER -

Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this